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Objective: To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further pro-
gression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin.
Methods: Patients were randomised 1:1:1:1:1 to: sprifermin 100 mg every 6 months (q6mo), 100 mg q12mo,
30 mg q6mo, 30 mg q12mo, or placebo for 18 months. SAR was defined as baseline medial or lateral mini-
mum joint-space width (mJSW) 1.53.5 mm and Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) pain score 4090 units. Follow-up to 3 years was included in the analysis. Treatment benefit
was explored by repeated measures, linear dose-effect trends by timepoint.
Results: The SAR comprised 161 (29%) of 549 patients. Mean difference (95% CI) in WOMAC pain at year 3 for
sprifermin 100 mg q6mo vs placebo SAR was -8.75 (-22.42, 4.92) for SAR vs 0.97 (-6.22, 8.16) for the intent-
to-treat population. SAR placebo patients lost more cartilage over 2 years than the modified ITT (mITT) pla-
cebo arm (mean change from baseline, mm [SD]: -0.05 [0.10] vs -0.02 [0.07]). Net total femorotibial joint
thickness gain with sprifermin 100 mg q6mo (adjusted mean difference from placebo [95% CI] was similar in
the SAR and in the mITT group: 0.06 [0.01, 0.11] vs 0.05 [0.03, 0.07]).
Conclusions: Selection for low mJSW and moderate-to-high pain at baseline resulted in more rapid disease
progression and demonstrated translation of structure modification (with maintained net benefit on total
cartilage thickness) into symptomatic benefit. This subgroup may represent a target population for future
trials.
Clinical trial registration: : NCT01919164.








c. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Osteoarthritis (OA) is a prevalent disease associated with pain,
reduced joint function, diminished quality of life, and a substantial
healthcare burden [1,2]. OA is characterised by structural alterations,
particularly progressive loss of articular cartilage [1]. Current OA drugsalleviate symptoms but do not prevent structural disease progression
[2,3]. Most symptom-targeting agents have short-term benefits [4] and
substantial safety considerations [5]. There is, therefore, an unmet need
for disease-modifying OA drugs (DMOADs) that offer structural improve-
ments and consequent symptomatic benefit in pain or function [68].
Sprifermin is a recombinant human fibroblast growth factor 18
investigated as a possible anabolic intra-articular (i.a.) DMOAD. Pre-
clinical studies indicate that the mode of action of sprifermin is to
stimulate chondrocytes and hyaline extracellular matrix synthesis
[912]. The phase II FORWARD trial demonstrated differences in lon-
gitudinal cartilage thickness change with sprifermin versus placebo
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3, significant dose-dependent effects on total femorotibial joint (TFTJ)
cartilage thickness (primary endpoint) were demonstrated. Two- and
3-year improvements in Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) scores and sub-scale scores were seen
in all treatment groups [13].
Recent literature supports selection of patients with modera-
tehigh WOMAC scores and low joint space width to improve detec-
tion of a pain response while enriching for structural progression
[1417] Such patients display greater cartilage loss than those with-
out joint space narrowing [18,19] and low pain frequency [20].
Insights from FORWARD suggest a floor effect due to the relatively
high proportion of patients with low pain (32% with WOMAC pain
sub-scale score <40/100) and relatively high minimum joint space
width (mJSW; 50% >3.7 mm) at baseline.
The post-hoc analysis described herein tested the hypothesis that
selection of a more homogenous OA patient subgroup from FOR-
WARD (subgroup at risk [SAR]) would show symptomatic benefit
over placebo in addition to structural modification. Sensitivity analy-
ses explored whether a mJSW- and pain-defined subgroup would
better differentiate from the intention-to-treat (ITT)/modified ITT
(mITT) cohort than a definition based on either mJSW or pain alone.
Methods
Study design
FORWARD was a multicentre, randomised, double-blind, placebo-
controlled, dose-finding, phase II, 5-year trial (NCT01919164). Details
of the methods have been reported [13]. Briefly, patients aged 4085
with symptomatic radiographic knee OA, Kellgren-Lawrence (KL)
grade 2 or 3, and medial mJSW 2.5 mm in the target knee were
randomised (1:1:1:1:1) to receive three once-weekly i.a. injections
of: 30 mg sprifermin every 6 months (q6mo) or q12mo; 100 mg spri-
fermin q6mo or q12mo; or placebo for 18 months (Fig. 1). The pri-
mary endpoint was change in TFTJ cartilage thickness from baseline
to 2 years. Total WOMAC and pain subscale scores were secondary
endpoints. At the time of this analysis, data from the 2-year treat-
ment period plus 1 year of follow-up (at Year 3) were available.
The ITT population (all randomised patients) was used for
WOMAC pain analyses; the mITT population (all ITT patients with
one baseline and 1 post-treatment qMRI assessment) was used for
qMRI efficacy analyses; the safety analysis population included all
patients who received 1 dose of treatment. All patients gave written
informed consent. The study was performed in accordance with the
Declaration of Helsinki.
Patient SAR
The baseline variables for selecting a subgroup that may poten-
tially benefit in terms of pain and structure modification were mJSW
andWOMAC pain [1418,21]
Based on published measurements for different mJSW strata
[17,22,23], mJSW limits of 1.53.5 mm (minimum measured medi-
ally or laterally, since FORWARD included patients with both medial
and lateral compartment disease) were selected.
WOMAC pain score selection of 4090 was consistent with estab-
lished study practice [21]. Sub-question A1, referring to pain on walk-
ing, was the only protocol-specified pain score (used at screening
only, but not at baseline). The current analysis evaluated consistency
of treatment effect across all pain endpoints.
Therefore, the subgroup formalised as a post-hoc analysis of a SAR
was defined as mJSW >1.5 to 3.5 mm, and WOMAC scores of
4090.
A ’non-SAR’ subgroup from the remainder of the ITT population
included patients with mJSW >1.5 mm who did not meet the SARWOMAC criteria and patients with mJSW >3.5 mm, regardless of
WOMAC pain score. Patients with mJSW <1.5 mm, missing mJSW or
WOMAC data were excluded.
Outcomes
TFTJ cartilage thickness was assessed by qMRI at baseline, before
the first injection of each cycle (6, 12 and 18 months) and at follow-
up visits (24 and 36 months), using 1.5 or 3 Tesla clinical MRI scan-
ners [13]. Pain was self-assessed as part of the 24-question WOMAC
questionnaire [13].
Key structural secondary endpoints included change from base-
line in TFTJ cartilage thickness at Year 3 and versus placebo. Key pain
secondary endpoints included change from baseline to Year 3 in
WOMAC sub-scores for the SAR, non-SAR subgroup, and ITT popula-
tion, difference in WOMAC sub-score versus placebo in the SAR, and
subgroups of patients with different baseline characteristics, as well
as percentage of patients with pain improvement scores 10 points
from baseline over 3 years. Clinically relevant individual improve-
ments in WOMAC pain have been described as 10 points from base-
line [24]. Also reported were patient-reported outcomes (PROs) at
Year 3 with sprifermin 100mg q6mo versus placebo in the SAR.
Differentiation of responses were evaluated by mJSW and pain
individually and together.
Safety, including adverse events (AEs) and serious AEs (SAEs), was
assessed up to 3 years.
Statistical analyses are described in the Supplement.
Results
Patients
The ITT population comprised 549 patients, of whom 161 (29%)
were classified as the SAR and 339 (62%) as the non-SAR subgroup
(Fig. 1). Forty-nine patients (9%) were not classifiable due to missing
data (n = 46) or having mJSW <1.5 mm at baseline (n = 3). The mITT
included 494 patients.
SAR baseline characteristics were similar to the ITT population in
terms of age, sex, race and body mass index (Table 1). More SAR
patients had KL grade 3, a lower median mJSW, and higher median
WOMAC pain than the ITT population (table S1).
WOMAC pain sub-score
WOMAC pain changes from baseline in placebo-treated patients
of the SAR were consistent with the ITT population (Fig. 2). At Year 3,
the placebo WOMAC pain score response from baseline was approxi-
mately a 20-point (SAR) and 24-point (ITT population) decrease
(Fig. 2).
Compared with the ITT population, a dose-dependent improve-
ment in WOMAC pain in the SAR was observed with sprifermin,
which increased to Year 3 (sprifermin 100 mg q6mo versus placebo,
p<0.05; Fig. 2). In the non-SAR subgroup, reduction in pain with pla-
cebo at Year 3 was numerically greater versus sprifermin 100 mg
q6mo (absolute mean difference: 6.45 points [95% CI  1.76;14.66];
Fig. S1). More than 95% of SAR sprifermin-treated patients (100 mg
groups) achieved a clinically relevant observed improvement from
baseline of 10 in WOMAC pain score at Year 3 (Fig. S2). There was
greater differentiation between sprifermin 100 mg q6mo and placebo
in WOMAC pain sub-score in the SAR versus either baseline charac-
teristic alone (Fig. 3).
Adjusted mean difference between SAR sprifermin 100 mg q6mo
and placebo at Years 2 and 3 were 5.82 (95% CI  18.87;7.23) and
8.75 (95% CI 22.42;4.92), respectively (Table 2). A sensitivity anal-
ysis (unadjusted mean difference in the descriptive results) showed
more pronounced differences between sprifermin and placebo. In the
Fig. 1. Study disposition.
* Reasons for withdrawal: adverse event (17), protocol non-compliance (12), withdrew consent (42), disease progression (3), death (1), other (23).
Table 1
Overall baseline characteristics in the ITT, SAR, and non-SAR populations.
ITT (n = 549) SAR (n = 161) Non-SAR subgroup
(n = 339)




Female,% 69.0 78.9 63.4
White race,% 80.0 78.9 79.1
Median BMI, kg/m2 28.6 29.6 27.8
KL grade 2,%* 69.0 47.2 78.2
KL grade 3,%* 31.0 52.8 21.8
Median mJSW, mm
(min, max)*
3.6 (1.0, 6.6) 2.8 (1.5, 3.5) 4.1 (1.7, 6.6)
Median WOMAC
pain (min, max)*
46.0 (10.0, 88.0) 54 (40.0, 86.0) 40.0 (10.0, 88.0)
*In the target knee. BMI, body mass index; ITT, intention-to-treat; KL, Kellgren-
Lawrence; mJSW, minimum joint space width; SAR, subgroup at risk; WOMAC,
Western Ontario and McMaster Universities Osteoarthritis Index.
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ent between sprifermin 100 mg q6mo and placebo (adjusted mean
difference at Year 3: 0.97 [95% CI 6.22;8.16]). The absolute mean
change from baseline in WOMAC sub-score at Year 3 in the non-SAR
subgroup was 6.45 (95% CI  1.76;14.66).
TFTJ cartilage thickness
SAR placebo-treated patients had numerically greater TFTJ carti-
lage loss between baseline and 2 years than the mITT population
(observed mean loss 0.05 vs 0.02 mm; Fig. 4). A similar difference
was observed between the SAR and non-SAR subgroup (Fig. S3). In
the SAR and mITT population, a nominally significant dose-depen-
dent effect of sprifermin on observed change in total cartilage thick-
ness was seen from Year 1 (Fig. 4). Increased cartilage thickness withsprifermin 100mg q6mo versus placebo at Year 2 was slightly greater
in the SAR (adjusted mean difference 0.06 mm [95% CI 0.01;0.11];
Table 3) versus the mITT population (0.05 mm [95% CI 0.02;0.08]).
While mean cartilage thickness decreased in all treatment groups
between Years 2 and 3 in both the SAR and mITT population, the
mean difference versus placebo at Year 2 remained similar up to Year
3 (Fig. 4). This was also true of the SAR and non-SAR subgroup
(Table 3, Fig. S3).Other PROs
Three-year findings for other PROs with sprifermin 100 mg q6mo
were consistent with WOMAC pain, including total WOMAC score,
WOMAC stiffness and function, total weight bearing, WOMAC pain
Q3 and Q4 score, knee pain on numerical rating scale, and patient
global assessment score (Fig. S4).Safety
The proportion of patients with AEs with sprifermin versus pla-
cebo in the SAR (99.2% vs 100.0%) was comparable to the safety anal-
ysis population (96.8% vs 98.1%), as were local AEs (table S2). More
placebo-treated patients in the SAR had SAEs versus the safety analy-
sis population (47.1% vs 33.6%) but SAEs were comparable for sprifer-
min-treated patients in the two groups (21.3% vs 23.6%). The
proportion of placebo-treated patients with musculoskeletal and
connective tissue disorder SAEs was 29.4% (SAR) and 13.1% (safety
analysis population). All SAEs were unrelated to sprifermin. There
was one patient death, due to gastric cancer, in the SAR placebo
group.
Fig. 2. Observed change in WOMAC pain sub-score at Year 3. CI, confidence interval; ITT, intention-to-treat; q6mo, every 6 months; q12mo, every 12 months; WOMAC, Western
Ontario and McMaster Universities Osteoarthritis Index.
Fig. 3. Observed mean difference in change from baseline to Year 3 in WOMAC pain sub-score (95% CI) with sprifermin 100 mg q6mo vs placebo* for subgroups of patients with dif-
ferent baseline characteristics. *N = number of participants receiving placebo vs sprifermin 100 mg q6mo. BL, baseline; ITT, intention-to-treat; mJSW, minimum joint space width;
q6mo, every 6 months; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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Both structural and symptomatic benefit are needed for an agent
to be considered a DMOAD [25], and clinical trials have previously
failed to demonstrate concomitant improvements in bothTable 2
Adjusted mean difference in WOMAC pain sub-score with s
the SAR.
Number of non-missing values (n) Adju
100m
Sprifermin 100 mg q6mo Placebo
Year 1 31 31 3.6
Year 1.5 31 28 4.8
Year 2 31 28 5.8
Year 3 28 27 8.7
* Repeated measure model with adjustment on baseline
difference generated by the creation of the subgroup and mi
y CIs are adjusted for multiplicity of treatment groups.
z Dose-effect trend test across all treatment groups for ad
CI, confidence interval; n, number of participants with chang
subgroup at risk; WOMAC, Western Ontario and McMaster Uoutcomes [7,2628]. This may be because patient populations
were too heterogeneous, typically including patients whose struc-
tural degradation and associated pain symptoms may progress at
different rates or not at all [7,14,29]. In addition, patients without
cartilage loss at baseline may not be expected to benefitprifermin 100 mg q6mo (n = 34) vs placebo (n = 33) in
sted* mean difference with sprifermin






and pooled country to account for potential baseline
ssing data.
justed values.
e from baseline available; q6mo, every 6 months; SAR,
niversities Osteoarthritis Index.
Table 3
Adjusted mean difference in total femorotibial cartilage thickness with sprifermin 100 mg q6mo (n = 34) vs placebo
(n = 33) in the SAR.
Number of non-missing values (n) Adjusted* mean difference with sprifermin
100mg q6mo vs placebo (95% CI)y
Trend testz
Sprifermin 100 mg q6mo Placebo
Year 1 29 29 0.02 (0.010.05) 0.049
Year 1.5 29 26 0.03 (0.010.08) 0.012
Year 2 29 27 0.06 (0.010.11) <0.001
Year 3 25 23 0.05 (0.010.12) 0.002
* Repeated measure model with adjustment on baseline and pooled country to account for missing data and
potential baseline difference generated by the creation of the subgroup and missing data.
y CIs are adjusted for multiplicity of treatment groups.
z Dose-effect trend test across all treatment groups for adjusted values from the repeated measure model.
CI, confidence interval; n, number of participants with change from baseline available; q6mo, every 6 months; SAR,
subgroup at risk.
Fig. 4. Observed change in total femorotibial joint cartilage thickness at Year 3. CI, confidence interval; mITT, modified intention-to-treat; q6mo, every 6 months; q12mo, every 12
months.
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patients whose disease progresses more rapidly may be more
likely to exhibit a symptomatic response to treatment [29]. In
this post-hoc analysis, we identified a subgroup of patients at risk
of structural and symptomatic progression during the trial, based
on baseline characteristics.
Although FORWARD met its primary endpoint on structure, there
was no differentiation from placebo regarding the key secondary
pain outcome. There are several possible reasons for this. Using i.a.
saline injections as a control may act as an active placebo [30], mask-
ing symptomatic improvements associated with sprifermin. It is
well-documented that placebos can yield a clinically relevant
response and it is plausible that i.a. saline injections exert effects
through the dilution of inflammatory components [31], making it
challenging to demonstrate an effect size between placebo and com-
parator. Furthermore, FORWARD was primarily designed as a dose-
finding, structural effects trial, not a pain trial; modern pain inclusion
criteria were not implemented. Routine and rescue pain medications
were monitored, but not restricted. The ~90% of patients in each
treatment group who took additional pain medications in the first
2 years may have contributed to a greater response with placebo.
While mean pain score differences between sprifermin 100 mg
and placebo were observed from 1.5 years, the dose-effect trend test
did not reach a nominal p-value <0.05 until Year 3 in the SAR. Com-
pared with the cartilage thickness effect, this time lag may have
occurred because the pain response was indirect and secondary to
structural modification. The delay could reflect a reduction in symp-
tomatic progression due to the structural modification with sprifer-
min in patients who would otherwise progress more rapidly if left
untreated. This underscores the time it takes for structural improve-
ment to translate into a symptomatic benefit, suggesting that it maynot always be measurable within a typical OA clinical trial timeframe
in unselected, heterogeneous patient populations. As with the ITT
population, a high proportion of SAR placebo-patients demonstrated
a WOMAC pain response that was initially comparable to sprifermin.
It is clear that selection of a SAR based on both mJSW and pain cri-
teria was more effective than selection based on either alone, an
important message for designers of future trials, although several
limitations must be considered. This post-hoc analysis was hypothe-
sis-generating in nature, and results need to be confirmed in inde-
pendent clinical trials. The SAR had missing data, some baseline
imbalances, and small sample sizes with outliers that may have
impacted the results. In addition, pain endpoints have large variabil-
ity. However, sensitivity analyses indicated that the observed mean
difference between sprifermin and placebo in WOMAC pain change
from baseline was larger than the adjusted mean difference, support-
ing the main SAR findings. At Year 3, a dose effect trend test gave a
nominal p value, <0.05. Finally, it is not known how many patients
the medication washout applied to.
Conclusion
Our findings indicate that, in addition to increasing cartilage
thickness, treatment with sprifermin may confer symptomatic bene-
fits, such as decreased pain. This is the first analysis to provide a proof
of concept that structure (cartilage thickness) modification in knee
OA by an i.a. drug may translate into symptomatic clinical benefit,
provided an adequate patient cohort with established disease is
selected and followed for a duration long enough to determine
potential symptom benefits. Furthermore, this analysis is the first to
suggest that enriching a trial population with low mJSW and high
WOMAC pain at baseline results in greater differentiation between a
H. Guehring et al. / Seminars in Arthritis and Rheumatism 51 (2021) 450456 455DMOAD and placebo in WOMAC pain. Selecting a more homogenous
patient population that is likely to progress within an OA clinical trial
timeframe may improve the ability to reach a symptomatic endpoint
and ultimately lead to the approval of potential DMOADs. The patient
subgroup identified in this analysis may represent a target population
for future clinical trials of sprifermin or other potential DMOADs.
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